• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Product › Details

drug development

	Next higher product group	drug discovery

Record changed: 2019-07-08

Advertisement

More documents for drug development

• [1] AiCuris Anti-infective Cures GmbH. (7/9/19). "Press Release: AiCuris and Lysando Join Forces in the Fight against Antimicrobial Resistance". Wuppertal & Balzers....
• [2] Photocure ASA. (7/1/19). "Press Release: Photocure and Asieris Enter into a Global Licensing Deal for Cevira with up to USD 250 Million in Milestones and Double-digit Royalties". Oslo....
• [3] Boehringer Ingelheim. (7/1/19). "Press Release: Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline with New First-in-Class Compound from Yuhan Corporation". Ingelheim & Seoul....
• [4] X-Biotix Therapeutics, Inc.. (7/1/19). "Press Release: X-Biotix Therapeutics Joins Antimicrobials Working Group". Washington, DC....
• [5] Polyphor Ltd.. (6/27/19). "Press Release: Polyphor Appoints Frank Weber as New Chief Medical and Development Officer". Allschwil....
• [6] Genfit S.A.. (6/24/19). "Press Release: Genfit and Terns Pharmaceuticals Announce $228MM Strategic Partnership to Develop and Commercialize Elafibranor in Greater China". Lille & Cambridge, MA....
• [7] Calliditas Therapeutics AB. (6/10/19). "Press Release: Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore"....
• [8] Sensorion S.A.. (5/27/19). "Press Release: Sensorion Announces the Signature of a Partnership Framework Agreement with Institut Pasteur on Gene Therapy Programs Targeting Hearing Loss". Montpellier....
• [9] Debiopharm International SA. (5/14/19). "Press Release: Debiopharm Awarded $2.1 Million from CARB-X in the Fight against a Highly Resistant Nosocomial-pneumonia Causing Superbug". Lausanne....
• [10] Alentis Therapeutics AG. (4/30/19). "Press Release: Alentis Therapeutics Launches, Raising CHF 12.5m in a Series A to Develop Novel Therapeutics in Advanced Liver Disease and Cancer". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.